Valuation GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.

Stocks

Market Closed - NSE India S.E. Other stock markets 07:05:07 2026-06-16 EDT			5-day change	1st Jan Change
2,202.80 ^INR	+3.78%		+0.37%	-10.95%

05-29	GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Dr. Simrat Sohal from Compliance Officer and Ceases to Be the Senior Management Personnel, Effective August 5, 2026	CI
05-13	GlaxoSmithKline Pharmaceuticals Clocks Higher Fiscal Q4 Consolidated Net Profit	MT

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	281,714	224,319	329,173	487,432	386,822	372,888	-
Change	-	-20.37%	46.74%	48.08%	-20.64%	-3.6%	-
Enterprise Value (EV)	256,351	207,663	329,173	487,432	386,822	372,888	372,888
Change	-	-18.99%	58.51%	48.08%	-20.64%	-3.6%	0%
P/E Ratio	16.6x	36.7x	55.8x	52.5x	37.3x	32.7x	29x
PBR	10.6x	12.9x	18.5x	25x	17.1x	14x	11.9x
PEG	-	-0.6x	-16.49x	0.9x	3.2x	3.3x	2.3x
Capitalization / Revenue	8.59x	6.9x	9.53x	13x	10.1x	8.89x	8.03x
EV / Revenue	0x	0x	0x	0x	0x	8.89x	8.03x
EV / EBITDA	0x	0x	0x	0x	0x	25.4x	22.4x
EV / EBIT	0x	0x	0x	0x	0x	27.1x	23.7x
EV / FCF	0x	0x	0x	0x	0x	32.2x	29x
FCF Yield	2.75%	1.96%	1.67%	2.6%	2.19%	3.11%	3.45%
Dividend per Share ²	30	32	32	42	57	29.5	29.5
Rate of return	1.8%	2.42%	1.65%	1.46%	2.5%	1.34%	1.34%
EPS ²	100	36.05	34.83	54.76	61.15	67.3	75.97
Distribution rate	30%	88.8%	91.9%	76.7%	93.2%	43.8%	38.8%
Net sales ¹	32,780	32,517	34,537	37,492	38,217	41,939	46,453
EBITDA ¹	8,273	8,043	9,087	11,774	13,092	14,683	16,675
EBIT ¹	7,592	7,385	8,390	11,106	12,428	13,760	15,728
Net income ¹	16,947	6,107	5,900	9,276	10,360	11,402	12,873
Net Debt	-25,363	-16,656	-	-	-	-	-
Reference price ²	1,662.95	1,324.15	1,943.10	2,877.30	2,283.40	2,201.15	2,201.15
Nbr of stocks (in thousands)	169,406	169,406	169,406	169,406	169,406	169,406	-
Announcement Date	5/16/22	5/17/23	5/17/24	5/13/25	5/13/26	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	33.05x	12.01x	24.74x	0.6%	1,007B
JOHNSON & JOHNSON	25.19x	5.81x	15.79x	2.26%	567B
ABBVIE INC.	27.13x	6.62x	13.53x	3.1%	392B
ROCHE HOLDING AG	17.5x	4.32x	10.61x	3.07%	328B
NOVARTIS AG	20.98x	5.43x	13.17x	2.95%	277B
ASTRAZENECA PLC	22.23x	4.65x	13.18x	1.88%	275B
NOVO NORDISK A/S	12.63x	4.73x	9.67x	3.97%	196B
AMGEN INC.	22.79x	6.1x	10.65x	2.88%	189B
GILEAD SCIENCES, INC.	-44.54x	5.38x	29.66x	2.61%	154B
Average	15.22x	6.12x	15.67x	2.59%	376.23B
Weighted average by Cap.	22.38x	7.41x	17.25x	2.12%